Home > Publications Database > Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine. > print

001     165134
005     20230915090606.0
024 7 _ |a 10.3390/toxins14080529
|2 doi
024 7 _ |a pmid:36006191
|2 pmid
024 7 _ |a pmc:PMC9413678
|2 pmc
024 7 _ |a altmetric:136935545
|2 altmetric
037 _ _ |a DZNE-2022-01439
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Scuteri, Damiana
|0 0000-0001-5846-7058
|b 0
245 _ _ |a Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine.
260 _ _ |a Basel
|c 2022
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1664543465_12115
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a CC BY: https://creativecommons.org/licenses/by/4.0/
520 _ _ |a OnabotulinumtoxinA, targeting the CGRP machinery, has been approved for the last two decades for chronic migraine prevention. The recently approved monoclonal antibodies (mAbs) directed towards the calcitonin gene-related peptide (CGRP) pathway open a new age for chronic migraine control. However, some 40% patients suffering from chronic migraine is still resistant to treatment. The aim of this work is to answer the following PICOS (participants intervention comparator outcome study design) question: Is there evidence of efficacy and safety of the combined administration of anti-CGRP mAbs and onabotulinumtoxinA in chronic migraine? A systematic review and meta-analysis [Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 recommendations] was made up to 19 April 2022. The results are encouraging: the combined treatment proved to afford ≥50% monthly headache days (MHDs)/frequency reduction respect to baseline in up to 58.8% of patients; in comparison, anti-CGRP mAbs reduce MHDs of 1.94 days from baseline and botulinum toxin of 1.86 days. Our study demonstrates for the first time that the combination therapy of onabotulinumtoxinA with anti-CGRP mAbs affords a reduction of 2.67 MHDs with respect to onabotulinumtoxinA alone, with moderate certainty of evidence. Adequately powered, good-quality studies are needed to confirm the response to combination therapy in terms of efficacy and safety. PROSPERO registration: CRD42022313640.
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a PRISMA 2020
|2 Other
650 _ 7 |a anti-CGRP monoclonal antibodies
|2 Other
650 _ 7 |a migraine
|2 Other
650 _ 7 |a onabotulinumtoxinA
|2 Other
650 _ 7 |a pooled analysis
|2 Other
650 _ 7 |a Antibodies, Monoclonal
|2 NLM Chemicals
650 _ 7 |a Botulinum Toxins, Type A
|0 EC 3.4.24.69
|2 NLM Chemicals
650 _ 7 |a Calcitonin Gene-Related Peptide
|0 JHB2QIZ69Z
|2 NLM Chemicals
650 _ 2 |a Antibodies, Monoclonal: therapeutic use
|2 MeSH
650 _ 2 |a Botulinum Toxins, Type A: therapeutic use
|2 MeSH
650 _ 2 |a Calcitonin Gene-Related Peptide: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Drug Therapy, Combination: adverse effects
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Migraine Disorders: prevention & control
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
700 1 _ |a Tonin, Paolo
|0 0000-0002-4867-1378
|b 1
700 1 _ |a Nicotera, Pierluigi
|0 P:(DE-2719)2010732
|b 2
|u dzne
700 1 _ |a Vulnera, Marilù
|b 3
700 1 _ |a Altieri, Giuseppina Cristina
|b 4
700 1 _ |a Tarsitano, Assunta
|b 5
700 1 _ |a Bagetta, Giacinto
|0 0000-0001-8540-6218
|b 6
700 1 _ |a Corasaniti, Maria Tiziana
|0 0000-0001-6472-0697
|b 7
770 _ _ |a Botulinum Neurotoxin: Shared/Common Mechanisms in the Treatment of Pain, Spasticity and Movement Disorders
773 _ _ |a 10.3390/toxins14080529
|g Vol. 14, no. 8, p. 529 -
|0 PERI:(DE-600)2518395-3
|n 8
|p 529
|t Toxins
|v 14
|y 2022
|x 2072-6651
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/165134/files/DZNE-2022-01439.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/165134/files/DZNE-2022-01439.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:165134
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2010732
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-05-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-05-04
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-05-04
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-05-04
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b TOXINS : 2021
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-08-26T14:06:59Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-08-26T14:06:59Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-08-26T14:06:59Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b TOXINS : 2021
|d 2022-11-11
920 1 _ |0 I:(DE-2719)1030000
|k Scientific board
|l Scientific board
|x 0
920 1 _ |0 I:(DE-2719)1013003
|k AG Bano
|l Aging and neurodegeneration
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1030000
980 _ _ |a I:(DE-2719)1013003
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21